BioLargo Valuation
| BLGO Stock | USD 0.17 0.01 5.56% |
BioLargo seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of BioLargo from analyzing the firm fundamentals such as Current Valuation of 52.87 M, profit margin of (1.29) %, and Return On Equity of -3.63 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that BioLargo's price fluctuation is out of control at this time. Calculation of the real value of BioLargo is based on 3 months time horizon. Increasing BioLargo's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioLargo otc stock is determined by what a typical buyer is willing to pay for full or partial control of BioLargo. Since BioLargo is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLargo OTC Stock. However, BioLargo's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.17 | Real 0.14 | Hype 0.17 |
The intrinsic value of BioLargo's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioLargo's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioLargo helps investors to forecast how BioLargo otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLargo more accurately as focusing exclusively on BioLargo's fundamentals will not take into account other important factors: About BioLargo Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of BioLargo. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of BioLargo based exclusively on its fundamental and basic technical indicators. By analyzing BioLargo's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of BioLargo's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioLargo. We calculate exposure to BioLargo's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioLargo's related companies.BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.
8 Steps to conduct BioLargo's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates BioLargo's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioLargo's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioLargo's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioLargo's revenue streams: Identify BioLargo's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioLargo's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioLargo's growth potential: Evaluate BioLargo's management, business model, and growth potential.
- Determine BioLargo's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioLargo's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
BioLargo Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 255.9 M | |
| Retained Earnings | -139.1 M |
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.